Ea2165-A Randomized Phase II Study Of Nivolumab After Combined Modality Therapy (Cmt) In High Risk Anal Cancer
Posted Date: May 15, 2019
- Investigator: Tahir Latif
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves Disease-Free Survival (DFS) compared with observation in patients with high risk anal carcinoma/
Criteria:
To Be Eligible: Patient Must 18 Years Of Age Or Older, Patient Must Be Diagnosed With Stage Iib,Iiia, Iiib, Or Iiic Squamous Cell Carcinoma Of The Anus, Must Be Nonpregnant And Nonbreastfeeding, No Organ Transplant History, No Current Uncontrolled Infection Or Illness,
Keywords:
Anal Cancer, Phase Ii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com